We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Marketing & Sales

News List

Japanese regulators hand first global approval to AbbVie, Boehringer Ingelheim's IL-23 inhibitor Skyrizi firstwordpharma
March 27, 2019
AbbVie announced Tuesday that the Japanese Ministry of Health, Labour and Welfare approved Skyrizi (risankizumab) for the treatment of plaque psoriasis, generalised pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults who have an
KOL Views: What to make of oral semaglutide’s performance in PIONEER 6? firstwordpharma
November 27, 2018
Novo Nordisk reported top-line results from the Phase III PIONEER 6 trial showing that oral semaglutide achieved an encouraging but non-significant reduction in major
US clears Loxo Oncology, Bayer's Vitrakvi for tumours driven by NTRK gene fusion, regardless of location firstwordpharma
November 27, 2018
The FDA announced Monday that it granted accelerated approval for Loxo Oncology and Bayer's Vitrakvi (larotrectinib) to treat adult and paediatric patients whose cancers have
China to reduce tariffs, increase imports of Indian medicines firstwordpharma
July 10, 2018
China's foreign ministry said Monday that India and China had agreed on reducing duties on Indian medicines, especially cancer drugs, reported the Hindustan Times.